Bisphosphonates Global Market Report 2025

The bisphosphonates market size has grown strongly in recent years. It will grow from $5.39 billion in 2024 to $5.7 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the increasing incidence of multiple myeloma, a rise in glucocorticoid-induced osteoporosis cases, the prevalence of sedentary lifestyles, greater availability of generic bisphosphonates, and the growing use of these medications in treating metastatic bone disease.

The bisphosphonates market size is expected to see strong growth in the next few years. It will grow to $7.07 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period can be attributed to increased investment in bone health research, rising demand for affordable osteoporosis treatments, a growing emphasis on elderly healthcare, expanding use of bisphosphonates in emerging markets, and heightened awareness driven by digital health campaigns. Key trends expected during this period include innovations in drug delivery systems, advanced formulations with enhanced bioavailability, the development of combination therapies, advancements in patient adherence technologies, and progress in personalized treatment approaches.

The rising prevalence of osteoporosis is expected to drive the growth of the bisphosphonates market in the coming years. Osteoporosis is a medical condition marked by weakened bones that are more susceptible to fractures. Its growing prevalence is mainly attributed to the aging global population, as bone density naturally declines with age, along with contributing lifestyle factors and a lack of adequate preventive measures. Bisphosphonates are effective in treating osteoporosis by slowing bone degradation, thereby strengthening bones and lowering fracture risk. For example, in August 2024, Healthy Bones Australia, an organization focused on bone health research and advocacy, reported that in 2023, there were an estimated 193,482 fractures linked to osteoporosis and osteopenia, with projections indicating a 34% increase to 237,632 fractures by 2033. Thus, the rising incidence of osteoporosis is a key factor fueling the growth of the bisphosphonates market.

The rise in research and clinical trials is expected to drive the growth of the bisphosphonates market in the coming years. Clinical trials are research studies involving human participants that assess the safety, effectiveness, and potential side effects of new treatments, drugs, or medical devices. This increase is largely fueled by the growing demand for innovative therapies to meet evolving healthcare needs and enhance patient outcomes. In the context of bisphosphonates, clinical research plays a critical role in advancing bone health treatments by examining their efficacy, safety, and long-term impact in managing conditions like osteoporosis and bone metastases. For example, in November 2023, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported a 4.3% increase in industry-initiated clinical trials in the UK, rising from 394 trials in 2021 to 411 in 2022. Thus, the growing focus on research and clinical trials is contributing significantly to the expansion of the bisphosphonates market.

In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for an undisclosed amount. This acquisition is intended to strategically enhance and diversify Abiogen’s rare disease portfolio by incorporating EffRx’s innovative therapies for musculoskeletal and rare conditions. It also supports Abiogen’s goal of expanding its international footprint and strengthening its capabilities in the development and commercialization of specialized treatments worldwide. EffRx Pharmaceuticals SA is a Switzerland-based specialty pharmaceutical company that produces and markets bisphosphonates for the treatment of osteoporosis.

Major players in the bisphosphonates market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Organon & Co., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Alkem Laboratories, Natco Pharma Ltd., Strides Pharma Science Limited, Radius Health Inc., Warner Chilcott.

North America was the largest region in the bisphosphonates market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bisphosphonates report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bisphosphonates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bisphosphonates are a group of drugs that help prevent bone loss by inhibiting the activity of osteoclasts, making them a primary therapy for osteoporosis and other bone-weakening conditions. They are frequently prescribed to lower the risk of fractures in individuals with low bone density, Paget’s disease, or bone metastases due to cancer. These medications aid in strengthening bones, increasing bone mineral density, and reducing fracture risk, especially in postmenopausal women and older adults.

The major types of bisphosphonates include alendronate, ibandronate, risedronate, and zoledronic acid. Alendronate is specifically used to treat and prevent bone-related disorders such as osteoporosis and Paget’s disease. These drugs can be administered through various routes, including oral, intravenous, subcutaneous, intraosseous, and intramuscular. They are available through hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. Primary applications include treating osteoporosis, Paget’s disease, and bone metastases, with end users ranging from hospitals and clinics to homecare settings and pharmaceutical retailers.

The bisphosphonates market research report is one of a series of new reports that provides bisphosphonates market statistics, including bisphosphonates industry global market size, regional shares, competitors with a bisphosphonates market share, detailed bisphosphonates market segments, market trends and opportunities, and any further data you may need to thrive in the bisphosphonates industry. This bisphosphonates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bisphosphonates market consists of sales of oral tablets, bisphosphonate capsules, bisphosphonate injections, oral solutions, and intravenous (IV) infusions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.